<DOC>
	<DOCNO>NCT01678781</DOCNO>
	<brief_summary>A study evaluate , country overall , change baseline irritable bowel syndrome quality life ( IBS QoL ) total score 4 8 week treatment Duspatalin® Dicetel® IBS patient .</brief_summary>
	<brief_title>Open International Study Quality Life Irritable Bowel Syndrome ( IBS ) Patients Before After 8 Weeks Treatment With Mebeverine/Pinaverium Bromide</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Mebeverine</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Pinaverium</mesh_term>
	<mesh_term>Alverine</mesh_term>
	<criteria>Irritable bowel syndrome patient diagnose Rome III criterion ( 18 year old ) Pregnancy lactation Specific contraindication mebeverine hydrochloride pinaverium bromide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Abdominal pain</keyword>
	<keyword>Diarrhea</keyword>
	<keyword>Mebeverine hydrochloride</keyword>
	<keyword>Constipation</keyword>
	<keyword>Pinaverium bromide</keyword>
	<keyword>Irritable bowel syndrome</keyword>
	<keyword>Bloating</keyword>
	<keyword>Quality life</keyword>
</DOC>